Premium
Bispecific radioligands targeting prostate‐specific membrane antigen and gastrin‐releasing peptide receptors on the surface of prostate cancer cells
Author(s) -
Liolios Christos,
Sachpekidis Christos,
Schäfer Martin,
Kopka Klaus
Publication year - 2019
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.3749
Subject(s) - glutamate carboxypeptidase ii , prostate cancer , receptor , gastrin releasing peptide , chemistry , prostate , cancer research , peptide , gastrin , antigen , cancer , medicine , bombesin , secretion , immunology , biochemistry , neuropeptide
Metastases of prostate cancer usually show highly heterogeneous or partly lost prostate‐specific membrane antigen (PSMA) expression. In order to image and treat both PSMA positive and negative tissues, the extension of PSMA tracer specificity to other receptors, also highly expressed on the surface of prostate cancer cells, has been suggested. Prostate cancer cells usually express both PSMA and gastrin‐releasing peptide (GRP) receptors; thus, bispecific heterodimeric molecules, addressing both targets at the same time, may significantly improve prostate cancer imaging and therapy. This article summarizes preclinical data regarding low‐molecular weight molecules targeting PSMA and GRP receptors.